We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Test Selectively Identifies Influenza A Virus H1N1

By LabMedica International staff writers
Posted on 11 May 2009
A test that has been developed for the new variant of the influenza A virus H1N1 will be launched initially in Europe and Asia.

TIB Molbiol (Berlin, Germany), a cooperation partner of Roche Applied Science (Indianapolis, IN, USA), announced that the company's LightMix A test has been optimized for Roche LightCycler 480 II, 2.0, and 1.2 systems and selectively identifies the new Influenza A H1N1 virus.

"We are proud of our contribution in the battle against a potential pandemic. More...
The new test proved its suitability this week, after identifying the virus in sample materials from Mexico," said Olfert Landt, TIB Molbiol.

Currently, there is no human vaccine on the market that protects against infection by influenza A virus H1N1. Standard therapy for the disease includes treatment with antiviral drugs such as Tamiflu or Relenza.

TIB Molbiol offers custom synthesis of oligonucleotides to a growing number of customers worldwide and is one of the first suppliers of synthetic DNA on the European market. The core competence of the company lies in the development of real-time polymerase chain reaction (RT-PCR) assays for medical diagnostics, life science research, and environmental analysis.

Related Links:
TIB Molbiol
Roche Applied Science


Gold Member
Collection and Transport System
PurSafe Plus®
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Gold Member
Ketosis and DKA Test
D-3-Hydroxybutyrate (Ranbut) Assay
Hemodynamic System Monitor
OptoMonitor
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: Residual leukemia cells may predict long-term survival in acute myeloid leukemia (Photo courtesy of Shutterstock)

MRD Tests Could Predict Survival in Leukemia Patients

Acute myeloid leukemia is an aggressive blood cancer that disrupts normal blood cell production and often relapses even after intensive treatment. Clinicians currently lack early, reliable markers to predict... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.